Why Intercept Pharmaceuticals, Inc. Shares Imploded

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Intercept Pharmaceuticals (NASDAQ: ICPT  ) , a biopharmaceutical company developing therapies to treat chronic liver diseases, fell as much as 36%, or $129 per share – it's fourth consecutive intraday move of at least $129 -- following comments made by its CEO called into question the future of its lead drug, obeticholic acid (OCA) for nonalcoholic steathohepatitis (NASH).

So what: Following Intercept's presentation at the JPMorgan Healthcare Conference yesterday, CEO Mark Pruzanski noted that his company may need the assistance of a larger drug maker (i.e., a partner) to help bring OCA to market. This only further complicates what has been a boom-and-bust past week for Intercept which exploded higher by more than 500% at the end of last week following the stoppage of a mid-stage trial for OCA on statistically significant efficacy. Intercept, however, has been slowed by a flat tire this week as cholesterol levels in those patients, specifically the bad kind, saw a marked increase and will need further investigating.

Now what: And I thought the five-day chart made me dizzy yesterday -- you should see it now! There are really a handful of variables at play here includes the safety of OCA as it relates to the increase in lipid levels, the efficacy as it relates to a largely unmet disease that could affect between 5 million and 6 million people in the U.S., and Intercept's need to have a larger pharmaceutical partner share development costs as well as handle an eventual commercial rollout if the drug is approved. In other words, with the share price having moved a minimum of $129 in each of the past four days, your best course of action is likely to stick to the sidelines and to let things settle down first.

Will this top stock leave Intercept in its dust in 2014?
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (3) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 14, 2014, at 3:30 PM, marp11 wrote:

    ARNA 10 bagger this year


  • Report this Comment On January 14, 2014, at 4:29 PM, TheStockDoctor wrote:

    The CEO is wise to be cautious. The FDA just took down a notch a great small company AEGR, pretending the CEO was too aggressive in the claims he made in a CNBC interview. Now the FDA has the DOJ involved with a subpoena that has helped knock share prices down more than 40% from their high half a year ago.

    So ICPT should learn from the problems of others and keep all comments tempered with the full disclaimer and legal-ese that makes life difficult for everyone.

  • Report this Comment On January 15, 2014, at 12:45 PM, TruffelPig wrote:

    To our talented fool Sean: (a) Do you know where cholesterol comes from? (b) the LDL story is a hype - I mean, compared to dying of a liver disease your LDL level increases modestly? Wow, tough choice, to die or to have a higher LDL?

    Please remain on the sidelines - write less of these "why a sack of rice fell in China" things and focus on something important. This is just promo stuff leading to NOTHING. This type of activity make me not renew my MF subscriptions (I HAD 4). In the maentime I make some money on this extremly promising company!


Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2794702, ~/Articles/ArticleHandler.aspx, 8/28/2015 11:10:22 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,586.72 -68.05 -0.41%
S&P 500 1,982.53 -5.13 -0.26%
NASD 4,804.84 -7.87 -0.16%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 10:53 AM
ICPT $191.58 Up +2.24 +1.18%
Intercept Pharmace… CAPS Rating: **